Should You Buy Integra LifeSciences Holdings C Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Integra LifeSciences Holdings C (IART) occupies a solid middle-ground position with a Quality of Company score of 6.9/10. At the current market price of $19.01, the investment case depends heavily on whether our 13 independent valuation models indicate a discount to fair value.
The short answer: 6 of 12 CirclFi valuation models project upside for Integra LifeSciences Holdings C (IART) at $19.01 — the models are evenly split, with a Quality Score of 6.9/10 and Value-Trap risk of —/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
Investment Thesis
The Bull Case
Target: $57.61 (+203.1% upside)
- According to the CirclFi Deep Alpha Valuation Engine, the Earnings Power Value (EPV) model targets a fair value of $57.61 (+203.1%), anchoring the bull case with a methodology that strips out growth assumptions to value sustainable earnings alone.
The Bear Case
Target: $4.96 (-73.9%)
- According to the CirclFi Deep Alpha Valuation Engine, the Markov DDM model sees the stock as overvalued with a fair value of $4.96 (-73.9%), suggesting that the market price embeds overly optimistic growth assumptions.
- According to the CirclFi Deep Alpha Valuation Engine, the wide model spread of +277.0% reflects fundamental divergence on key assumptions (growth, cost of capital) depending on the methodology.
The Bottom Line
Integra LifeSciences Holdings C at $19.01 is a genuine coin-flip in our framework. The 6–5 bull-bear split across 12 models, +277.0% model spread, and composite fair value of $20.89 (+9.9% avg.) argue for a watchlist position rather than a high-conviction bet. Quality at 6.9/10 adds some comfort to the mix.
These are quantitative model outputs, not investment recommendations. Integra LifeSciences Holdings C's future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
Frequently Asked Questions
Should I buy IART stock right now?
Based on CirclFi's multi-model analysis, 6 of 12 models see upside for IART at $19.01. The models are divided, which means the investment case depends heavily on your assumptions about Integra LifeSciences Holdings C's future. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Integra LifeSciences Holdings C?
Key risks include: wide model disagreement (1061% spread), signaling high uncertainty; general market and sector-specific risks affecting Surgical & Medical Instruments & Apparatus companies. Always diversify and consult a financial advisor.
How does IART compare to its competitors?
Among Surgical & Medical Instruments & Apparatus peers, IART holds a Quality Score of 6.9/10. Comparable companies include DXCM (QOC 10.0), IRMD (QOC 10.0), PODD (QOC 10.0). The relative ranking helps investors identify whether IART offers better fundamental quality than alternatives in the same sector.
Is IART a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. IART's Quality Score of 6.9/10 suggests moderate fundamentals — not a clear long-term hold without further research into growth catalysts. Check our full data page for all 13 model estimates.
What price should I buy IART at?
CirclFi does not provide target buy prices or price alerts. However, our 12 active models produce fair value estimates ranging from $4.96 to $57.61. At $19.01, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for IART.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad